Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

New FIBRONEER results were presented by Boehringer Ingelheim at this year’s European Respiratory Society (ERS) International ...

With phase I/II data in hand, Taiho Pharmaceutical Co. Ltd. and Cullinan Therapeutics Inc. began filing a rolling NDA to the U.S. FDA for accelerated approval of zipalertinib to treat patients with ...

The most common chronic progressive fibrosing ILD is IPF.1,2 PPF is another form of progressive fibrotic lung disease that ...

Until then, my family chooses to remain thankful for the available PF treatments and hopeful about the advancements that are sure to come. A diagnosis of PF will change your life, but life is for the ...

Columnist Samuel Kirton attended the Pulmonary Fibrosis Foundation's Summit 2025, where the group's five-year strategic plan was unveiled.

Treatment for progressive pulmonary fibrosis (PPF) depends on the underlying etiology of the condition, symptom severity at diagnosis, and the presence of comorbidities. PPF refers to a progressive ...

Add articles to your saved list and come back to them any time. Nine’s long-time weather presenter Livinia Nixon will sign off this month, after 20 years in the role. “I’ve been on air for more of my ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...